Patient Strategy Manager
- Location
- Guaynabo, PR
- Employment
- Full Time
- Work model
- On-Site
- Level
- Mid
- H-1B history
- 57 approvals (FY2023)
- Posted
About this role
At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits. This is work that transforms the lives of patients, and the careers of those who do it. At Bristol Myers Squibb, we are inspired by a single vision – transforming patients’ lives through science. In oncology, hematology, immunology and cardiovascular disease – and one of the most diverse and promising pipelines in the industry – each of our passionate colleagues contributes to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Position
Summary The Patient Strategy Manager is a member of the Brand Team who translates brand strategy into patient-facing execution across the Hematology, Oncology and Cell Therapy portfolio. The role owns patient journey insight, direct-to-consumer (DTC) omnichannel content, the tracking and local adaptation of US patient materials, and professional society and congress engagement, and supports Corporate Affairs-led disease awareness campaigns. Reports to the Business Unit Director; Brand Leads and the Corporate Affairs Lead are the primary internal customers.
Key Responsibilities
Patient Strategy Execution: Co-creates the annual patient plan with Brand Leads and the Corporate Affairs Lead, escalating competing priorities to the Business Unit Director. Translates brand strategy into patient-facing execution plans; Brand Leads retain accountability for brand strategy and performance. Accountable for the quality, timeliness and compliance of patient-facing tactics, and for defining and reporting their success metrics. Manages assigned budget and agency/vendor support, and uses field and market insight to continuously improve patient engagement. Patient Journey and Insight: Owns the patient journey for each brand, from diagnosis through treatment initiation and adherence, identifying friction points that limit outcomes. Maintains the cell therapy referral-to-treatment pathway, including referral, apheresis, bridging therapy, caregiver requirements and treating center logistics. Integrates market research, BI&A analytics, secondary data, and field and Corporate Affairs insight into patient segmentation and actionable recommendations. Omnichannel and DTC Content: Owns end-to-end DTC patient content, from omnichannel strategy and creation through deployment, including Spanish-language development and cultural adaptation. HCP-facing content remains with Brand Leads. Partners with the Omnichannel COE and BI&A to measure and optimize DTC channel performance. US Materials Tracking, Adaptation and Local Approval: Monitors all US disease awareness (unbranded) and product-related (branded) patient materials across the portfolio, maintaining a central tracker of new releases, updates, label changes and withdrawals. Assesses each US material for relevance to Puerto Rico patients and recommends whether to use as-is, adapt, adjust or not deploy locally, prioritizing alignment with Brand Leads and the Corporate Affairs Lead. Leads the adaptation process: Spanish translation and linguistic quality review, cultural and health-literacy adjustments, and alignment with local labeling, access and patient support programs. Coordinates with US content owners on source files, usage rights and change notifications, and guides each material through local Medical, Legal and Regulatory review and approval. Maintains version control, approval status and expiration/re-certification dates, ensuring only current, locally approved versions are in use and that materials are updated or